Daniel Gregory López Rodríguez MD, MBA

Experience

• 

  CEDPEC, COMOP, CECyC Pharma

  Jan 2007 - Nov 2011

  CLINICAL STUDIES COORDINATOR, CLINICAL RESEARCH, RESEARCHER OF BIOEQUIVALENCE STUDIES

  • Management of work teams (minimum 12, maximum 30 people).• Led the development of 64 clinical studies from phase I to IV in attachment to PCBs / ICH.• Led and developed 15 bioequivalence protocols with adherence to BPC / ICH.• Elaborated and updated PNO's for the development of clinical studies, (40 PNO's).• Maintained close communication with the Ethics Committee to submit protocols, safety reports, deviations and closings of clinical studies.• Attended feasibility visits, monitoring and auditing by the sponsor or the CRO, (without major findings). Show less

• 

  PHARMED RESOLUTIONS. M�XICO D.F

  Jan 2010 - Apr 2013

  Graduate teacher
• 

  Laboratorios PiSA

  Dec 2011 - Apr 2013

  CLINIC MONITOR SR

  • Created the clinical research area, (I developed 17 PNO's).• Management of work teams (4 internal clinical monitors and 3 external monitors).• Developed therapeutic bioequivalence studies, (8 clinical studies), in adherence to BPC / ICH.• Made feasibility visits to researchers (10) and CRO's (4).• Carried out initial visits, (5 home visits).• Carried out monitoring and co-monitoring visits.• Reviewed monitoring reports to resolve findings.• Carried out follow-up visits, face-face, (medical manager).• Attended audit by regulatory entity COFEPRIS, (1, no major findings). Show less

• 

  Ipsen

  Apr 2013 - Jan 2015

  • Budget management, ($ 3 MP).• Management of work teams, (1 senior monitor and 3 external suppliers).• Obtained the recommendations for the use of Botulin Toxin in congenital equine foot, (Advisory Board, 12 members).• Developed continuing medical education programs for physical medicine and rehabilitation, (30 presentations).• Inclusion of Botulin Toxin to Seguro Popular.• Update 20 PNOs.• Obtained the approval of promotional materials for Botulin Toxin in cerebral palsy and spasticity by COFEPRIS, (10 materials).• Implemented pharmacovigilance unit according to requirements of National Pharmacovigilance Center• Answered 260 medical information requests in 24 hours.• Report 489 Drug Reactions according to the requirements of the National Pharmacovigilance Center.• Trained sales force in key messages of promotional materials for Botulin Toxin, (20 people).• Trained to sales force in pharmacovigilance, (drug reactions report, 20 people, increase 30%). Show less • Management of Budgets, ($ 3 MP).• Management of work teams, (6 monitors, 3 suppliers).• Developed phase IV clinical studies, in adherence to the BPC / ICH.• Selected researchers for clinical studies, (90 researchers, 40 sites) and Contract Research Organizations, (3 CRO's).• Prepared a scientific agenda for the researchers' meetings.• Carried out researchers' meetings, (3 meetings of 90 people).• Reviewed monitoring reports to resolve findings.• Carried out follow-up meetings, face-face, (with principal investigators, clinical monitors and the medical director). Show less

  • MEDICAL AFFAIRS MANAGER

    Apr 2014 - Jan 2015

  • MANAGER RESEARCH

    Apr 2013 - Apr 2014
• 

  Sanofi

  Feb 2015 - now

  Flu | PPH | Travel & Endemic vaccines franchisesDemonstrate value for the business and customers via coaching, developing and leading the MSL team aligned to the FOUR core accountability areas: (1) Scientific Engagement (2) Insights Generation (3) Support Data Generation (4) Internal CollaborationCo-create/develop Country Medical Plans (with TA Medical Manager, Medical Director or MSL Head) and lead team execution to ensure alignment to medical priorities whilst leveraging all available MSL tools (i.e. Scientific Engagement Model).Ensure individual and team performance goals are set and met through monitoring metrics, resources and budgets ensuring excellence in execution and achieving KPIs.Ensure continuous talent engagement and retention strategies are in place utilizing clear career pathway and development plans.Ensure that MSLs engage in fair and balanced scientific exchanges with key external stakeholders by maintaining relevant, robust and current clinical / scientific knowledge of healthcare landscape.Ensure all compliance and governance processes are adhered to. Show less Flu | PPH | Travel & Endemic vaccines franchisesBe the trusted scientific partner to key external experts by conducting timely, appropriate and frequent scientific exchanges to enhance the understanding of the scientific and medical value of our products.Execute on stakeholder engagement plans to gather data, develop and share medical insights that contribute to enhancement of Sanofi’s key medical messages, plans and future research. Keep abreast of medical and scientific developments in the therapeutic field to help identify and critically assess research opportunities and to play a supportive role in the execution of evidence generation plans to enhance the value of our products in a real-world setting Recognize, record and share insights that deepen our understanding of the needs of patients, consumers, regulators, payers, and healthcare providers and proactively contributes towards identifying unmet needs.Maintain effective and appropriate communication among internal stakeholders (Medical Affairs colleagues, Medical Information and Commercial Operations) while maintaining full compliance with relevant company, industry, legal and regulatory requirementsDemonstrate operational understanding and risk management by ensuring excellence in execution of all governance processes. Show less

  • PPH MCO Medical Manager

    Jul 2024 - now

  • Senior Medical Affairs Manager

    Sept 2021 - Jul 2024

  • Medical Scientific Liaison Manager

    Nov 2019 - Sept 2021

  • Medical Scientific Liaison

    Apr 2016 - Nov 2019

  • Local Pharmacovigilance Officer (LPO)/ Medical Information and Local Pharmacovigilance Contact (LPC)

    Feb 2015 - Apr 2016